Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") to certain executives, officers, directors and consultants of the Company pursuant to the Company’s Amended and Restated Restricted Share Unit Plan, of which one third vests six months after the grant date, another one third after twelve months and the remaining balance after eighteen months.
Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the issued and outstanding securities and securities convertible into securities of GoldCoast Resource Corp. (the "Target" or "GoldCoast"), a corporation existing under the laws of Ontario (the "Acquisition").The Acquisition constitutes a "Change of Business" under the Canadian Securities Exchange ("CSE") policies.
TORONTO, ONTARIO, July 7, 2025 – Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), is pleased to announce that it has successfully closed the second tranche (“Tranche 2”) of its previously announced non‑brokered private placement (the “Offering”), relying on the accredited investor exemption under section 2.3 of National Instrument 45-106 — Prospectus Exemptions.
Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes.
Psyence Group Inc are pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.
Psyence Group Inc announces that the Company will be consolidating all of its issued and outstanding share capital (the “Common Shares”) on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the “Share Consolidation”), effective April 23, 2025 with a record date of April 23, 2025 (the “Record Date”).
Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.
Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB).
Psyence Group hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.
Per the terms of the Disposal, Psyence Biomed will issue to Psyence Group 2,000,000 shares of its common stock. PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development.
